Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind placebo-controlled phase III trial of GM1 for prevention of paclitaxel (albumin-bound)-induced peripheral neuropathy in breast cancer
CTR20252247Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of monosialotetrahexosylganglioside in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Qilu Pharmaceutical. Started Aug 2025; status: active.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on CTR20252247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252247.